Engineering a recombination-resistant live attenuated vaccine candidate with suppressed interferon antagonists for PEDV.

J Virol · 2025 · PMC12282079 · PMID 40503881

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

The infectious titers showed a clear trend: icPC22A exhibited the highest titer, followed by dORF3-EGFP and RMTv1, which had comparable titers, while all three double IFN antagonist mutants (RMTv1-nsp1 + nsp15, RMTv1-nsp1 + nsp16, and RMTv1-nsp15 + nsp16) displayed significantly reduced titers.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.